CME
HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME

Sentinel Lymph Node Biopsy in Male Patients with Early Breast Cancer

TEST_code
CME Activity Information
Release Date: May 23, 2007
Most Recent Review: May 23, 2007*
Most Recent Update: May 23, 2007
Date Credit Expires: May 23, 2009
Time to Complete: 1 hour
Medium: Internet Online
*Click here to learn more about our review process.
Instructions for Participation

  1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
  2. Study the educational activity
  3. Complete the CME quiz and evaluation
  4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

    *The CME quiz and evaluation must be completed by May 23, 2009, in order to receive the credit or participation certificate.

 

Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment.

Learning Objectives
After completing this course, the reader should be able to:
  1. Evaluate the feasibility of sentinel lymph node biopsy in male breast cancer patients.
  2. Determine which male breast cancer patients can be candidates for sentinel lymph node biopsy.
  3. Identify the main biological features of male breast cancer and evaluate differences with respect to female breast cancer.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Institutes of Health Foundation for Advance Education in the Sciences (NIH/FAES) and The Oncologist. The NIH/FAES is accredited by the ACCME to provide continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the NIH/FAES to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity. The faculty and planners have indicated that they have no relevant commercial relationships. For a list of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Author Disclosure(s)
Oreste Gentilini, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy. Telephone: 39-02-57489376; Fax: 39-02-57489780; E-mail: oreste.gentilini{at}ieo.it.
Disclosures: The author has indicated no relevant commercial relationships.

Eduardo Chagas, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Stefano Zurrida, M.D.

Credentials: Department of Breast Surgery and University of Milan School of Medicine, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Mattia Intra, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Concetta De Cicco, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Concetta De Cicco, M.D.

Credentials: Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Giovanna Gatti, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Luzemira Silva, M.D.

Credentials: Department of Breast Surgery, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Giuseppe Renne, M.D.

Credentials: Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Enrico Cassano, M.D.

Credentials: Breast Imaging Unit, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Umberto Veronesi, M.D.

Credentials: Department of Breast Surgery and Scientific Director, European Institute of Oncology, Milan, Italy.
Disclosures: The author has indicated no relevant commercial relationships.

Commercial Support
Non-governmental supporters of this activity: AstraZeneca, Bristol-Myers Squibb Oncology, Pfizer, and sanofi-aventis

Hardware/Software Requirements
The Oncologist CME Online supports the following browsers: Current production versions of Opera, Safari, Firefox, Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh version of Explorer was discontinued in June 2003, and is not supported.

Other Links
Disclaimer
Privacy statement

Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu

HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME
Copyright © 2008 by AlphaMed Press.